- Report
- October 2023
- 178 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 181 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- December 2024
- 85 Pages
Spain
From €3327EUR$3,500USD£2,795GBP
- Report
- December 2024
- 87 Pages
Spain
From €3327EUR$3,500USD£2,795GBP
- Report
- November 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 173 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2023
- 133 Pages
North America
From €3803EUR$4,000USD£3,195GBP
- Report
- January 2024
- 143 Pages
Global
From €4040EUR$4,250USD£3,394GBP
- Report
- August 2023
- 145 Pages
Global
From €2995EUR$3,150USD£2,516GBP
- Report
- May 2023
- 147 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- May 2023
- 147 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- March 2023
Global
From €6084EUR$6,400USD£5,111GBP
- Report
- October 2024
- 104 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Book
- June 2020
- 198 Pages
- Report
- November 2021
- 545 Pages
Global
From €3803EUR$4,000USD£3,195GBP
- Report
- November 2021
- 1165 Pages
Global
From €5704EUR$6,000USD£4,792GBP
- Report
- July 2024
- 280 Pages
Global
From €2524EUR$2,655USD£2,120GBP
- Book
- May 2022
- 512 Pages
- Book
- April 2022
- 352 Pages
- Book
- October 2020
- 288 Pages

Epigenomics is a field of genomics that studies the regulation of gene expression through chemical modifications of DNA and its associated proteins. It focuses on the heritable changes in gene expression that occur without changes in the underlying DNA sequence. These modifications, known as epigenetic marks, are involved in a variety of biological processes, including development, aging, and disease.
Epigenomics research has been used to identify biomarkers for cancer diagnosis and prognosis, as well as to develop new therapeutic strategies. It has also been used to study the effects of environmental factors on gene expression, such as nutrition, stress, and exposure to toxins.
The epigenomics market is expected to grow significantly in the coming years, driven by increasing investments in research and development, technological advancements, and the growing prevalence of cancer and other diseases.
Some companies in the epigenomics market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, Merck KGaA, and Oxford Nanopore Technologies. Show Less Read more